Tumor response assessment on imaging following immunotherapy
AM Berz, C Dromain, N Vietti-Violi, S Boughdad… - Frontiers in …, 2022 - frontiersin.org
In recent years, various systemic immunotherapies have been developed for cancer
treatment, such as monoclonal antibodies (mABs) directed against immune checkpoints …
treatment, such as monoclonal antibodies (mABs) directed against immune checkpoints …
Impact of PET/CT for assessing response to immunotherapy—A clinical perspective
D Lang, G Wahl, N Poier, S Graf, D Kiesl… - Journal of Clinical …, 2020 - mdpi.com
Cancer immunotherapy using immune-checkpoint inhibitors (ICI) has revolutionized the
therapeutic landscape of various malignancies like non-small-cell lung cancer or melanoma …
therapeutic landscape of various malignancies like non-small-cell lung cancer or melanoma …
Pretreatment 18F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non–small cell lung cancer: a …
G Dissaux, D Visvikis, R Da-Ano… - Journal of Nuclear …, 2020 - Soc Nuclear Med
The aim of this retrospective multicentric study was to develop and evaluate a prognostic
18F-FDG PET/CT radiomic signature in early-stage non–small cell lung cancer patients …
18F-FDG PET/CT radiomic signature in early-stage non–small cell lung cancer patients …
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
Objectives:(1.1) to evaluate the association between baseline 18F-FDG PET/CT semi-
quantitative parameters of the primary lesion with progression free survival (PFS), overall …
quantitative parameters of the primary lesion with progression free survival (PFS), overall …
Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma …
Purpose Ipilimumab induces durable remission in about 15–20% of patients with metastatic
melanoma. However, reliable predictors of response to ipilimumab are currently lacking …
melanoma. However, reliable predictors of response to ipilimumab are currently lacking …
[HTML][HTML] Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a …
Background Reliable predictive and prognostic markers are still lacking for patients treated
with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC) …
with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC) …
Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1/PD-L1 blockade therapy in patients with non–small cell lung cancer
Purpose The aim of this study was to compare the Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1, the immune RECIST (iRECIST) criteria, and the Positron Emission …
Tumors (RECIST) 1.1, the immune RECIST (iRECIST) criteria, and the Positron Emission …
Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic …
T Ling, L Zhang, R Peng, C Yue, L Huang - Frontiers in Immunology, 2022 - frontiersin.org
Purpose This study aimed to investigate the value of 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (18F-FDG PET/CT) in predicting early …
emission tomography/computed tomography (18F-FDG PET/CT) in predicting early …
First-line pembrolizumab mono-or combination therapy of non-small cell lung cancer: baseline metabolic biomarkers predict outcomes
D Lang, L Ritzberger, V Rambousek, A Horner, R Wass… - Cancers, 2021 - mdpi.com
Simple Summary Positron-emission tomography/computed tomography (PET/CT) is used for
staging of non-small cell lung cancer (NSCLC) and can help to estimate prognosis in …
staging of non-small cell lung cancer (NSCLC) and can help to estimate prognosis in …